The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
Elı́as Campo1Haematopathology Section, Hospital Clínic of Barcelona, Institut d’Investigaciones Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Centro de Investigación Biomédica en Red de Cancer (CIBERONC), Barcelona, Spain;Elaine S. Jaffe2Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD;James R. Cook3Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH;Leticia Quintanilla‐Martínez4Institute of Pathology and Neuropathology, Eberhard Karls University of Tübingen and Comprehensive Cancer Center, University Hospital Tübingen, Tübingen, Germany;Steven H. Swerdlow5Department of Pathology, University of Pittsburgh School of Medicine, University of Pittsburgh, Pittsburgh, PA;Kenneth C. Anderson6Dana-Farber Cancer Institute, Boston, MA;Pierre Brousset7Department of Pathology, Institut Universitaire du Cancer de Toulouse-Oncopole, and Laboratoire d’Excellence Toulouse Cancer, Toulouse, France;Lorenzo Cerroni8Department of Dermatology, Medical University of Graz, Graz, Austria;Laurence de Leval9Institute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and Lausanne University, Lausanne, Switzerland;Stefan Dirnhofer10Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland;Ahmet Doǧan11Laboratory of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY;Andrew L. Feldman12Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN;Falko Fend4Institute of Pathology and Neuropathology, Eberhard Karls University of Tübingen and Comprehensive Cancer Center, University Hospital Tübingen, Tübingen, Germany;Jonathan W. Friedberg13Wilmot Cancer Institute, University of Rochester, Rochester, NY;Philippe Gaulard14Department of Pathology, University Hospital Henri Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP), Créteil, France;Paolo GhiaIRCCS Ospedale San RaffaeleSteven M. Horwitz17Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;Rebecca L. King12Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN;Gilles Salles17Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;Jesús F. San Miguel18Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, CIBERONC, Pamplona, Spain;John F. Seymour19Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia;Steven P. Treon6Dana-Farber Cancer Institute, Boston, MA;Julie M. Vose20Division of Hematology-Oncology, Department of Internal Medicine, University of Nebraska Medical Center, University of Nebraska, Omaha, NE;Emanuele Zucca21Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, and Institute of Oncology Research, Università della Svizzera Italiana, Bellinzona, Switzerland;Ranjana H. Advani22Stanford Cancer Center, Blood and Marrow Transplant Program, Stanford University, Stanford, CA;Stephen M. Ansell23Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN;Wing-Yan AuCarlos Barrionuevo25Department of Pathology, Instituto Nacional de Enfermedades Neoplásicas, Faculty of Medicine, Universidad Nacional Mayor de San Marcos, Lima, Peru;Leif Bergsagel26Division of Hematology, Department of Internal Medicine, Mayo Clinic, Phoenix, AZ;Wing C. Chan27Department of Pathology, City of Hope National Medical Center, Duarte, CA;Jeffrey I. Cohen28Medical Virology Section, Laboratory of Infectious Diseases, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Bethesda, MD;Francesco d’Amore29Department of Hematology, Aarhus University Hospital, Aarhus, Denmark;Andrew Davies30Cancer Research UK Centre, Centre for Cancer Immunology, Faculty of Medicine, Southampton General Hospital, University of Southampton, Southampton, United Kingdom;Brunangelo Falini31Institute of Hematology and Center for Hemato-Oncology Research, Hospital of Perugia, University of Perugia , Perugia, Italy;Irene M. Ghobrial32Harvard Medical School, Harvard University, Boston, MA;John R. Goodlad33National Health Service Greater Glasgow and Clyde, Glasgow, United Kingdom;John G. Gribben34Department of Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom;Eric D. Hsi35Department of Pathology, Wake Forest School of Medicine, Wake Forest University, Winston-Salem, NC;Brad S. Kahl36Oncology Division, Washington University School of Medicine, Washington University in St. Louis, St. Louis, MO;Won-Seog Kim37Hematology and Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea;Shaji Kumar23Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN;Ann S. LaCasce6Dana-Farber Cancer Institute, Boston, MA;Camille Laurent7Department of Pathology, Institut Universitaire du Cancer de Toulouse-Oncopole, and Laboratoire d’Excellence Toulouse Cancer, Toulouse, France;Georg Lenz38Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany;John P. Leonard39Weill Department of Medicine, Weill Medical College, Cornell University, New York, NY;Michael P. Link40Department of Pediatrics, Division of Pediatric Hematology-Oncology, Stanford University School of Medicine, Stanford University, Stanford, CA;Armando López‐Guillermo41Department of Hematology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain;María‐Victoria Mateos42Department of Hematology, Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Centro de Investigación del Cancer, Universidad de Salamanca, Salamanca, Spain;Elizabeth Macintyre43Laboratoire d’Onco-Hématologie, AP-HP, Hôpital Necker-Enfants Malades, Université de Paris Cité and Institut Necker-Enfants Malades, Paris, France;Ari Melnick44Division of Hematology and Oncology, Weill Medical College, Cornell University, New York, NY;Franck Morschhauser45Department of Hematology, Centre Hospitalier Universitaire de Lille, University Lille, Lille, France;Shigeo Nakamura46Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan;Marina Narbaitz47Department of Pathology, Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina and Fundacion para combatir la leucemia (FUNDALEU), Buenos Aires, Argentina;Astrid PavlovskyStefano Pileri49Haematopathology Division, IRCCS, Istituto Europeo di Oncologia, Milan, Italy;Miguel Á. Piris50Jiménez Díaz Foundation University Hospital, Universidad Autónoma de Madrid, Madrid, Spain;Barbara Pro51Division of Hematology and Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL;S. Vincent Rajkumar12Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN;Steven T. Rosen52Beckman Research Institute, and Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA;Birgitta Sander53Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden;Laurie H. Sehn54Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada;Margaret A. Shipp6Dana-Farber Cancer Institute, Boston, MA;Sonali M. Smith55Section of Hematology/Oncology, University of Chicago, Chicago, IL;Louis M. Staudt56Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD;Catherine Thieblemont57Service Hémato-Oncologie, AP-HP, Hôpital Saint-Louis, Paris, France;Thomas Tousseyn59Department of Pathology, Universitair Ziekenhuis Leuven Hospitals, Leuven, Belgium;Wyndham H. Wilson56Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD;Tadashi Yoshino60Department of Pathology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, Okayama, Japan;Pier Luigi Zinzani61Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seragnoli", Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy;Martin Dreyling62Department of Medicine III, Ludwig-Maximilians-University Hospital, Munich, Germany;David W. Scott54Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada;Jane N. Winter63Feinberg School of Medicine, Northwestern University, Chicago, IL; andAndrew D. Zelenetz17Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;
2022en
ABI
Annotatsiya
Since the publication of the Revised European-American Classification of Lymphoid Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have been generated through iterative international efforts to achieve broad consensus among hematopathologists, geneticists, molecular scientists, and clinicians. Significant progress has recently been made in the characterization of malignancies of the immune system, with many new insights provided by genomic studies. They have led to this proposal. We have followed the same process that was successfully used for the third and fourth editions of the World Health Organization Classification of Hematologic Neoplasms. The definition, recommended studies, and criteria for the diagnosis of many entities have been extensively refined. Some categories considered provisional have now been upgraded to definite entities. Terminology for some diseases has been revised to adapt nomenclature to the current knowledge of their biology, but these modifications have been restricted to well-justified situations. Major findings from recent genomic studies have impacted the conceptual framework and diagnostic criteria for many disease entities. These changes will have an impact on optimal clinical management. The conclusions of this work are summarized in this report as the proposed International Consensus Classification of mature lymphoid, histiocytic, and dendritic cell tumors.
Hali tarjima qilinmagan
Identifikatorlar
Iqtiboslar va manbalar
2 ta iqtibos0 ta foydalanilgan manba